<DOC>
	<DOCNO>NCT01015625</DOCNO>
	<brief_summary>Primary Operation synchronous metastasize invasive breast cancer evaluate use local therapy</brief_summary>
	<brief_title>Primary Operation SYnchronous meTastasized InVasivE Breast Cancer</brief_title>
	<detailed_description>This study prospective , randomize , multicentre , study concern influence local treatment patient synchronous metastasize breast cancer . Patients stratify inclusion accord centre , menopausal status ( pre-menopausal , post-menopausal ) , hormone-receptor status ( ER-/PR-/not determinable ; PR and/or Er+ ) , HER-2 status ( positive vs. negative/not determinable ) , grade ( G1/G2/not determinable vs. G3 ) , location metastasis ( visceral ± v bone ) , organs metastasis ( single organ vs multiple organ ) use first line chemotherapy ( anthracycline ± vs. taxane v others ) . Thereafter patient randomly assign receive either local therapy breast ( lumpectomy mastectomy + axillary surgery /± radiotherapy ) versus local therapy . Systemic therapy administer center policy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients age ≥ 18 year Eastern Cooperative Oncology Group Performance Status 0 2 Untreated synchronous metastasize invasive carcinoma breast primary tumor situ ( bilateral synchronous metastasize breast cancer patient eligible ) The primary tumor must identify may size , however , primary resection resection free margin must possible Invasive adenocarcinoma breast histological examination The metastatic site must identify radiological assessment ( Computer Tomography chest abdomen OR ultrasound chest x ray visceral metastasis ; bone scan AND/OR computer tomography AND/OR magnetic resonance bone metastasis ) . A biopsy necessary . Written informed consent must obtain documented prior begin protocol specific procedure accord local regulatory requirement able comply protocol requirement treatment followup period . Patients R0 resection ( microscopic free margin ) clinically questionable Inflammatory cancer Patients brain metastasis Patients eligible general anesthesia operation Patients without metastatic breast cancer ( patient tumor marker value ( CEA , CA153 ) normal level without radiological proven evidence metastasis eligible study ) Patients second untreated malignancy Any previous malignancy treat curative intent patient diseasefree 5 year exception : ( ) carcinoma situ cervix , ( b ) squamous carcinoma skin , ( c ) basal cell carcinoma skin Patients recurrent cancer disease Pregnant lactate woman Patients allow part another local therapy trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ABCSG</keyword>
	<keyword>POSYTIVE</keyword>
	<keyword>growth factor</keyword>
	<keyword>median survival</keyword>
	<keyword>surgery demand</keyword>
	<keyword>surgical therapy</keyword>
	<keyword>blood specimen</keyword>
	<keyword>tissue specimen</keyword>
	<keyword>VEGF</keyword>
	<keyword>TGF</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>stem cell</keyword>
</DOC>